Circulation 2021 Aug 23;144(8):615-637. Epub 2021 Jun 23.
Pittsburgh Heart, Lung and Blood Vascular Medicine Institute (T.S., L.W., C.E.-D., S.A.H., E.R.R., M.R.D., J.J.B., Y.T., M.R., S.S., C.S.H., D.G., D.A.G., E.A.G., S.Y.C., A.C.S., C.F.M., M.T.G.), University of Pittsburgh School of Medicine, PA.
Background: Many patients with heart failure with preserved ejection fraction have metabolic syndrome and develop exercise-induced pulmonary hypertension (EIPH). Increases in pulmonary vascular resistance in patients with heart failure with preserved ejection fraction portend a poor prognosis; this phenotype is referred to as combined precapillary and postcapillary pulmonary hypertension (CpcPH). Therapeutic trials for EIPH and CpcPH have been disappointing, suggesting the need for strategies that target upstream mechanisms of disease. Read More